<p>Inventiva S.A. 贊助的 ADR (NASDAQ:IVA - 獲取免費報告) 的股票在週二交易中表現出強勁的交易量。交易期間共成交 1,311,257 股，較前一交易日的 457,841 股增加了 186%。該股票最後交易價格為 $5.5150，之前收盤價為 $5.01。</p>
<h2>分析師評級調整</h2>
<p>多家券商最近對 IVA 發佈了報告。Weiss Ratings 在 1 月 22 日的研究報告中重申了對 Inventiva 的 &#34;賣出 (d-)&#34; 評級。瑞銀集團在 1 月 7 日的報告中開始覆蓋 Inventiva，給予 &#34;買入&#34; 評級和 $12.00 的目標價。Leerink Partners 在 1 月 12 日的研究報告中開始覆蓋 Inventiva，給予 &#34;跑贏大盤&#34; 評級和 $12.00 的目標價。巴克萊在 1 月 27 日的研究報告中開始覆蓋 Inventiva，給予 &#34;增持&#34; 評級和 $18.00 的目標價。最後，HC Wainwright 在 1 月 28 日的研究報告中對 Inventiva 設定了 $24.00 的目標價，並給予公司 &#34;買入&#34; 評級。三位分析師對該股票給予了強烈買入評級，六位給予了買入評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 &#34;買入&#34;，共識目標價為 $16.56。</p>
<p><strong>獲取我們最新的 IVA 股票分析</strong></p>
<h2>Inventiva 價格表現</h2>
<p>該股票的 50 日移動平均線為 $6.03，200 日移動平均線為 $5.36。</p>
<p>Inventiva (NASDAQ:IVA - 獲取免費報告) 最近於 2 月 15 日發佈了其財報。公司報告本季度每股收益為 ($0.16)。該季度的收入為 $0.01 萬美元。分析師平均預計 Inventiva S.A. 贊助的 ADR 本財年的每股收益將為 -2.08。</p>
<h2>對 Inventiva 的對沖基金看法</h2>
<p>機構投資者和對沖基金最近增加或減少了對該股票的持股。Paradigm Biocapital Advisors LP 在第四季度收購了 Inventiva 的新頭寸，價值 $18,600,000。ADAR1 Capital Management LLC 在第四季度收購了 Inventiva 的新頭寸，價值約 $12,601,000。瑞銀集團 AG 在第四季度將其在 Inventiva 的持股增加了 28,881.6%。瑞銀集團 AG 目前擁有 2,643,702 股該公司股票，價值 $12,293,000，此前在上一季度購買了額外的 2,634,580 股。SymBiosis Capital Partners LLC 在第四季度收購了 Inventiva 的新股份，價值約 $12,090,000。最後，Millennium Management LLC 在第四季度將其在 Inventiva 的持股增加了 2,267.7%。Millennium Management LLC 目前擁有 2,652,570 股該公司股票，價值 $12,334,000，此前在上一季度購買了額外的 2,540,540 股。機構投資者持有該公司 19.06% 的股票。</p>
<h2>關於 Inventiva</h2>
<p>(獲取免費報告)</p>
<p>Inventiva NASDAQ: IVA 是一家臨牀階段的生物製藥公司，專注於小分子療法的發現、開發和商業化，以治療代謝、炎症和纖維化疾病。公司的核心專長在於調節核受體和信號通路，這些受體和通路調控纖維化、炎症和代謝功能障礙。Inventiva 的科學平台整合了藥物化學、體外和體內藥理學以及轉化科學，以推進多樣化的治療候選藥物管線。</p>
<p>公司的主要資產，lanifibranor (IVA337)，是一種在開發階段的全 PPAR 激動劑，針對非酒精性脂肪性肝炎 (NASH)，並在臨牀前和臨牀研究中顯示出抗炎和抗纖維化效果。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票比 Inventiva 更好</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 $1,000 在 Inventiva 嗎？</h2>
<p>在你考慮 Inventiva 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買... 而 Inventiva 並不在名單上。</p>
<p>雖然 Inventiva 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

<p>Inventiva (NASDAQ:IVA) 的交易量顯著增加，交易了 1,311,257 股，比前一交易日上漲了 186%。股價從 $5.01 上漲至 $5.5150。分析師的評級意見不一，Weiss Ratings 給出了 “賣出” 評級，而 UBS 等機構則將目標價設定在 $12.00 到 $24.00 之間。機構投資者持有該股票的 19.06%。該公司專注於開發代謝和炎症疾病的治療方案。儘管目前的評級為 “買入”，但一些分析師建議有更好的投資選擇</p>

<p>Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) shares saw strong trading volume on Tuesday . 1,311,257 shares changed hands during trading, an increase of 186% from the previous session's volume of 457,841 shares.The stock last traded at $5.5150 and had previously closed at $5.01.</p>
<div class="lb-trans"><p>Inventiva S.A. 贊助的 ADR (NASDAQ:IVA - 獲取免費報告) 的股票在週二交易中表現出強勁的交易量。交易期間共成交 1,311,257 股，較前一交易日的 457,841 股增加了 186%。該股票最後交易價格為 $5.5150，之前收盤價為 $5.01。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>A number of brokerages have recently issued reports on IVA. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Inventiva in a research note on Thursday, January 22nd. UBS Group assumed coverage on Inventiva in a report on Wednesday, January 7th. They set a &#34;buy&#34; rating and a $12.00 price target for the company. Leerink Partners started coverage on Inventiva in a research report on Monday, January 12th. They set an &#34;outperform&#34; rating and a $12.00 price target on the stock. Barclays began coverage on Inventiva in a research note on Tuesday, January 27th. They issued an &#34;overweight&#34; rating and a $18.00 price objective on the stock. Finally, HC Wainwright set a $24.00 target price on Inventiva and gave the company a &#34;buy&#34; rating in a research report on Wednesday, January 28th. Three analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of &#34;Buy&#34; and a consensus price target of $16.56.</p>
<div class="lb-trans"><p>多家券商最近對 IVA 發佈了報告。Weiss Ratings 在 1 月 22 日的研究報告中重申了對 Inventiva 的 &#34;賣出 (d-)&#34; 評級。瑞銀集團在 1 月 7 日的報告中開始覆蓋 Inventiva，給予 &#34;買入&#34; 評級和 $12.00 的目標價。Leerink Partners 在 1 月 12 日的研究報告中開始覆蓋 Inventiva，給予 &#34;跑贏大盤&#34; 評級和 $12.00 的目標價。巴克萊在 1 月 27 日的研究報告中開始覆蓋 Inventiva，給予 &#34;增持&#34; 評級和 $18.00 的目標價。最後，HC Wainwright 在 1 月 28 日的研究報告中對 Inventiva 設定了 $24.00 的目標價，並給予公司 &#34;買入&#34; 評級。三位分析師對該股票給予了強烈買入評級，六位給予了買入評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 &#34;買入&#34;，共識目標價為 $16.56。</p>
</div><p><strong>Get Our Latest Stock Analysis on IVA</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 IVA 股票分析</strong></p>
</div><h2>Inventiva Price Performance</h2>
<div class="lb-trans"><h2>Inventiva 價格表現</h2>
</div><p>The stock has a 50-day moving average of $6.03 and a 200 day moving average of $5.36.</p>
<div class="lb-trans"><p>該股票的 50 日移動平均線為 $6.03，200 日移動平均線為 $5.36。</p>
</div><p>Inventiva (NASDAQ:IVA - Get Free Report) last released its earnings results on Sunday, February 15th. The company reported ($0.16) EPS for the quarter. The business had revenue of $0.01 million for the quarter. On average, analysts expect that Inventiva S.A. Sponsored ADR will post -2.08 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Inventiva (NASDAQ:IVA - 獲取免費報告) 最近於 2 月 15 日發佈了其財報。公司報告本季度每股收益為 ($0.16)。該季度的收入為 $0.01 萬美元。分析師平均預計 Inventiva S.A. 贊助的 ADR 本財年的每股收益將為 -2.08。</p>
</div><h2>Hedge Funds Weigh In On Inventiva</h2>
<div class="lb-trans"><h2>對 Inventiva 的對沖基金看法</h2>
</div><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Paradigm Biocapital Advisors LP acquired a new position in shares of Inventiva during the fourth quarter worth $18,600,000. ADAR1 Capital Management LLC acquired a new position in Inventiva in the 4th quarter worth about $12,601,000. UBS Group AG boosted its stake in shares of Inventiva by 28,881.6% during the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company's stock valued at $12,293,000 after purchasing an additional 2,634,580 shares in the last quarter. SymBiosis Capital Partners LLC acquired a new stake in shares of Inventiva during the fourth quarter valued at about $12,090,000. Finally, Millennium Management LLC raised its holdings in Inventiva by 2,267.7% in the 4th quarter. Millennium Management LLC now owns 2,652,570 shares of the company's stock valued at $12,334,000 after buying an additional 2,540,540 shares during the last quarter. Institutional investors own 19.06% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近增加或減少了對該股票的持股。Paradigm Biocapital Advisors LP 在第四季度收購了 Inventiva 的新頭寸，價值 $18,600,000。ADAR1 Capital Management LLC 在第四季度收購了 Inventiva 的新頭寸，價值約 $12,601,000。瑞銀集團 AG 在第四季度將其在 Inventiva 的持股增加了 28,881.6%。瑞銀集團 AG 目前擁有 2,643,702 股該公司股票，價值 $12,293,000，此前在上一季度購買了額外的 2,634,580 股。SymBiosis Capital Partners LLC 在第四季度收購了 Inventiva 的新股份，價值約 $12,090,000。最後，Millennium Management LLC 在第四季度將其在 Inventiva 的持股增加了 2,267.7%。Millennium Management LLC 目前擁有 2,652,570 股該公司股票，價值 $12,334,000，此前在上一季度購買了額外的 2,540,540 股。機構投資者持有該公司 19.06% 的股票。</p>
</div><h2>About Inventiva</h2>
<div class="lb-trans"><h2>關於 Inventiva</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Inventiva NASDAQ: IVA is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company's core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva's scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.</p>
<div class="lb-trans"><p>Inventiva NASDAQ: IVA 是一家臨牀階段的生物製藥公司，專注於小分子療法的發現、開發和商業化，以治療代謝、炎症和纖維化疾病。公司的核心專長在於調節核受體和信號通路，這些受體和通路調控纖維化、炎症和代謝功能障礙。Inventiva 的科學平台整合了藥物化學、體外和體內藥理學以及轉化科學，以推進多樣化的治療候選藥物管線。</p>
</div><p>The company's lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.</p>
<div class="lb-trans"><p>公司的主要資產，lanifibranor (IVA337)，是一種在開發階段的全 PPAR 激動劑，針對非酒精性脂肪性肝炎 (NASH)，並在臨牀前和臨牀研究中顯示出抗炎和抗纖維化效果。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Inventiva</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Inventiva 更好</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Inventiva Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Inventiva 嗎？</h2>
</div><p>Before you consider Inventiva, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Inventiva 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買... 而 Inventiva 並不在名單上。</p>
</div><p>While Inventiva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Inventiva 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Inventiva（NASDAQ:IVA）交易量異常高 - 仍然是買入的好時機嗎？